Onderneming Barinthus Biotherapeutics plc
Aandelen
BRNS
US91864C1071
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
2,18 USD | +1,63% | -12,80% | -40,92% |
Vakgebied
Aantal werknemers: 130
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Immunotherapies and Vaccines
100,0
%
| 45 | 100,0 % | 1 | 100,0 % | -98,21% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United Kingdom and United States
100,0
%
| 45 | 100,0 % | 1 | 100,0 % | -98,21% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
William Enright
CEO | Chief Executive Officer | 61 | 01-08-19 |
Gemma Brown
DFI | Director of Finance/CFO | 34 | 01-09-21 |
Nadège Pelletier
CTO | Chief Tech/Sci/R&D Officer | 46 | 01-02-23 |
Investor Relations Contact | - | 01-10-22 | |
Graham Griffiths
PRN | Corporate Officer/Principal | 45 | 01-10-17 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Karen Dawes
BRD | Director/Board Member | 72 | 01-03-21 |
William Enright
CEO | Chief Executive Officer | 61 | 01-08-19 |
Anne Phillips
BRD | Director/Board Member | 70 | 21-02-21 |
Robin Wright
CHM | Chairman | 59 | 01-10-18 |
Director/Board Member | 61 | 01-01-18 | |
Alex Hammacher
BRD | Director/Board Member | 43 | 01-01-20 |
Joseph Scheeren
BRD | Director/Board Member | 68 | 31-03-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 38 643 540 | 37 217 593 ( 96,31 %) | 0 | 47,98 % |
Aandeel B | 1 | 38 921 212 | 0 | 0 |
Bedrijfsgegevens
Sector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-40,92% | 84,85 mln. | |
+25,69% | 47,9 mld. | |
+46,90% | 41,42 mld. | |
-3,46% | 40,7 mld. | |
-6,20% | 28,92 mld. | |
+9,17% | 25,55 mld. | |
-20,42% | 19,27 mld. | |
+0,17% | 12,15 mld. | |
+28,07% | 12,14 mld. | |
-1,24% | 11,99 mld. |
- Beurs
- Aandelen
- Koers BRNS
- Onderneming Barinthus Biotherapeutics plc